Baminercept (BG 9924, TT-47) is an Ig fusion protein targeting the lymphotoxin beta receptor (LTbetaR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-alpha1beta2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögrens syndrome[1][2].
Molecular Weight:
(93.76 kDa)
Purity:
99.97
CAS Number:
[909110-25-4]
Target:
CXCR,TNF Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
